Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16)
Year: 2025
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Authors: Hyehyun Jeong, Changhoon Yoo, Shinkyo Yoon, Jae Lyun Lee, Kyu-pyo Kim, Baek-Yeol Ryoo, Jaekyung Cheon, Minkyu Jung, Joo-Hwan Park, Ju Won Kim, Beodeul Kang, Sora Kang, Se Jun Park, Hyeon-Su Im, Jee Hyun Kim, Junghun Kang, Chang Ohk Sung, Ji-Hye Oh, Hongseok Yun, Sejoon Lee, Yaewon Yang, Jieun Lee, Inho Park, Inho Park, Sohyun Hwang, Ryul Kim, Jeong Seok Lee, Inkeun Park, Inkeun Park
Institutions: Asan Medical Center, University of Ulsan, Korea Advanced Institute of Science and Technology, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, CHA University Bundang Medical Center, CHA University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Gachon University, Gachon University Gil Medical Center, Gachon University Medical Center, Seoul National University, Korea University, Seoul National University Bundang Hospital, Korea University Anam Hospital, Chungnam National University, Chungnam National University Hospital, Ulsan University Hospital, Gyeongsang National University, Gyeongsang National University Hospital, Seoul National University Hospital, Chungbuk National University Hospital, Gangnam Severance Hospital
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: Ministry of Health and Welfare
Award: G4403730658
OpenAlex ID: W4416189497